Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.
ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.
iTAC Software AG specializes in manufacturing execution systems (MES) tailored for the global manufacturing industry. The company offers a suite of advanced solutions including iTAC.ARTES, which serves as middleware for enterprise applications on a Java EE platform, and iTAC.MES.Suite, designed to improve production efficiency. Additionally, their offerings include iTAC.embedded.Systems for traceability in Industry 4.0 applications, iTAC.Trace.Server for autonomous production environments, and iTAC.smart.Devices that facilitate system integration at the manufacturing level. iTAC also provides a cloud-based development platform called iTAC.Enterprise.Framework. Beyond software, the company delivers a range of services such as consulting, educational support, and 24/7 assistance. iTAC Software serves various sectors, including automotive, electronics, medical technology, and energy. Founded in 1998 and headquartered in Montabaur, Germany, the company also has a presence in Detroit, Michigan.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Infitel International
Venture Round in 2004
Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. Through its research initiatives, the company seeks to create innovative therapeutics that address significant unmet medical needs in the field of neuroscience.
MediGene is a biotechnology company that focuses on immuno-oncology, specifically developing engineered T cell receptor (TCR-T) therapies aimed at treating various solid tumors with significant unmet medical needs. The company operates primarily in two segments: Immunotherapies, which include T-cell receptor-based adoptive T-cell therapies and dendritic cell (DC) vaccines, and Other products. MediGene has a presence in the United States, Germany, and Asia, with most of its revenue generated from its operations in Germany. Through its innovative therapies, MediGene aims to address critical challenges in cancer treatment.
SelectX Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the discovery and development of aminoglycoside therapeutics to address unmet medical needs. The company is advancing its lead candidate, SXP2523, a next-generation aminoglycoside antibiotic aimed at treating drug-resistant gram-negative infections acquired in hospital settings. Additionally, SelectX is developing an inhaled aminoglycoside antibiotic intended for patients with Cystic Fibrosis and other respiratory diseases who face similar drug resistance challenges. Beyond antibiotics, the company is also focused on identifying and optimizing non-antibiotic aminoglycoside leads to target critical biological pathways, including cell migration and the correction of nonsense mutations. SelectX Pharmaceuticals was originally known as OmniScience Pharmaceuticals Inc. before rebranding in September 2002.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.
Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders in the United States and internationally. The company’s primary product, Ampyra (dalfampridine), is an oral medication approved to enhance walking in patients with multiple sclerosis. Additionally, Acorda markets Inbrija, an inhalation powder for the treatment of OFF periods in individuals with Parkinson's disease. The company's pipeline includes rHIgM22, which has completed Phase I trials for multiple sclerosis, and Cimaglermin alfa, currently in Phase Ib trials for heart failure. Acorda has established a collaboration with Biogen for the development and commercialization of Ampyra. Founded in 1995 and based in Ardsley, New York, Acorda Therapeutics aims to improve the quality of life for those affected by neurological conditions.
Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.
ClearCube Technology specializes in centralized and virtualized computing solutions, having pioneered the industry with the invention of the blade PC. The company provides a comprehensive range of specialized PCoIP desktop zero clients, which connect to optimized compute and storage host platforms tailored for different user needs, including both task-oriented and highly specialized engineering applications. ClearCube's product offerings include secure zero clients with integrated security features, designed for seamless compatibility with VMware Horizon virtualization products. Their solutions are widely adopted across various sectors, including federal agencies, healthcare, and finance, where they are valued for their ability to enhance security and reduce costs in centralization and virtualization efforts. ClearCube's commitment to meeting diverse IT requirements is further exemplified through their provision of ready-to-ship VDI endpoints and customizable hardware, ensuring optimal performance and expert support for businesses across multiple industries.
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).
Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.
Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.
Alfabet is a company that specializes in change management software aimed at enhancing enterprise information technology architecture planning. Founded in 1997 and based in Berlin, with a U.S. headquarters in Cambridge, Massachusetts, Alfabet offers its planningIT software, which integrates business priorities with IT deliverables, facilitating strategic planning and management of IT resources to align with business goals. Unlike traditional solutions that provide only static views of priorities and infrastructure, Alfabet's approach delivers a holistic, collaborative framework that ensures continuous transparency in managing evolving IT and business processes. The company serves a global community of 40,000 IT professionals across various industries, including automotive, financial services, telecommunications, and logistics. Its notable clients include major international corporations such as Credit Suisse, Munich Re, BMW, and Deutsche Bahn.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
ParadigmGenetics is a biotechnology company at the forefront of life science and gene discovery, focused on metabolic disorders. Leveraging cutting-edge technology and research methodologies, ParadigmGenetics strives to develop innovative solutions that contribute to the diagnosis, treatment, and prevention of metabolic disorders, aiming to make significant strides in the fields of biotechnology and human health.
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.
SelectX Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the discovery and development of aminoglycoside therapeutics to address unmet medical needs. The company is advancing its lead candidate, SXP2523, a next-generation aminoglycoside antibiotic aimed at treating drug-resistant gram-negative infections acquired in hospital settings. Additionally, SelectX is developing an inhaled aminoglycoside antibiotic intended for patients with Cystic Fibrosis and other respiratory diseases who face similar drug resistance challenges. Beyond antibiotics, the company is also focused on identifying and optimizing non-antibiotic aminoglycoside leads to target critical biological pathways, including cell migration and the correction of nonsense mutations. SelectX Pharmaceuticals was originally known as OmniScience Pharmaceuticals Inc. before rebranding in September 2002.
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. It offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. The company's products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. The company was founded in 2002 and is headquartered in Miramar, Florida.
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.
IC Mechanics is changing the way Smart MEMS Sensor ICs are designed, manufactured and employed. Compared to existing MEMS smart sensors, those from IC Mechanics will: Cost less Have higher sensitivity Be capable of higher bandwidth Be of a smaller size and lower mass This is possible through the combination of a novel sensor geometry and manufacturing process that is based on commodity CMOS VLSI wafers. By breaking through current standards for cost, bandwidth, sensitivity, and mass, IC Mechanics' smart sensors will enable the creation of a world of new devices, new applications and new markets. IC Mechanics products will target a wide range of OEMs requiring very low-cost, highly-integrated motion sensing and motion control ICs.
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
Iolon, Inc. is a privately held company specializing in optical networking components. It develops high-performance tunable devices designed for advanced fiber optic networks. The company's initial offering is a high-powered, external cavity tunable laser source suitable for high bit rate and long-haul applications. Iolon plans to expand its product range to include tunable filters, optical switches, polarization controllers, spectral monitors, and universal transponders. The technology platform employed by Iolon supports advanced automation for high-volume manufacturing and is based on patented micro-optics, MEMS, and sophisticated servo control technologies. Their products are utilized by customers in various applications, including the transmission, monitoring, and reception of optical signals, as well as in testing and measurement equipment.
Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.
Talia is a top-tier provider of Internet, voice, and video services, recognised as a market leader throughout the Middle East, Africa, and Europe. Experts in satellite, voice, video, and broadcast communications, Talia provide global network coverage, enabling enterprises, PTTs, mobile carriers, and broadcasters to connect to the largest global meet me room, and linking the major regional telecoms hubs around the world.
EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in developing innovative pharmaceutical products aimed at treating pain and cancer. The company employs a unique topical delivery approach for its prescription pain medications, which allows for targeted drug administration, distinguishing its products from traditional systemic or transdermal methods. EpiCept is focused on establishing partnerships for co-marketing, co-promotion, licensing, and distribution of its products, thereby enhancing its market presence. The company has implemented a robust patent strategy to protect its product portfolio, which is anticipated to possess significant market potential.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
ClearCube Technology specializes in centralized and virtualized computing solutions, having pioneered the industry with the invention of the blade PC. The company provides a comprehensive range of specialized PCoIP desktop zero clients, which connect to optimized compute and storage host platforms tailored for different user needs, including both task-oriented and highly specialized engineering applications. ClearCube's product offerings include secure zero clients with integrated security features, designed for seamless compatibility with VMware Horizon virtualization products. Their solutions are widely adopted across various sectors, including federal agencies, healthcare, and finance, where they are valued for their ability to enhance security and reduce costs in centralization and virtualization efforts. ClearCube's commitment to meeting diverse IT requirements is further exemplified through their provision of ready-to-ship VDI endpoints and customizable hardware, ensuring optimal performance and expert support for businesses across multiple industries.
Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.
Vividence
Series D in 2000
Vividence offers e-businesses with market information services and evaluation applications. It provides consulting services that focus on online customer experience, market trends, and industry strategies. Vividence enables individuals to earn gift cards by evaluating and giving feedback on e-commerce sites. Vividence was founded in 1998 and is based in San Mateo, California.
NanoGram Corporation is a nanotechnology company focused on developing and manufacturing advanced products for photovoltaics, electronics, and displays. It offers a customized application-specific nanotechnology platform that produces nanoscale compositions for various sectors, including optical, electronic, imaging, biomedical, and energy applications. The company has successfully incubated and spun out two firms, NeoPhotonics and NanoGram Devices. With a presence in Japan through its Tokyo office and a strategic partnership with Nagase & Co., Ltd / Nagase ChemteX Corporation, NanoGram is expanding its footprint in the region. Additionally, its office in Seoul, South Korea, supports its growth in the Korean market.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.
HepaVec AG
Series A in 2000
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
Gold Wire Technology is a U.S.-based software company that specializes in network configuration management tools designed for large data communication distributors. Founded in 1997 and acquired by Intelliden in 2004, the company develops and supports solutions that ensure the integrity of multi-vendor infrastructures for enterprises operating in sectors such as financial services, retail, automotive, healthcare, and pharmaceuticals. Gold Wire Technology's software enables effective control and management of service configurations for internet service providers, focusing on the needs of organizations that rely on revenue or compliance-critical networks.
EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in developing innovative pharmaceutical products aimed at treating pain and cancer. The company employs a unique topical delivery approach for its prescription pain medications, which allows for targeted drug administration, distinguishing its products from traditional systemic or transdermal methods. EpiCept is focused on establishing partnerships for co-marketing, co-promotion, licensing, and distribution of its products, thereby enhancing its market presence. The company has implemented a robust patent strategy to protect its product portfolio, which is anticipated to possess significant market potential.
Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.
Neolinear is a software developer specializing in analog and mixed-signal silicon design. The company's technology plays a crucial role in the development of mixed-signal chips that integrate both analog and digital circuitry, primarily targeting the consumer and communications markets. As semiconductors become more differentiated by their analog components, Neolinear's rapid analog design solutions are essential for enhancing the performance and functionality of these chips.
Sunol Molecular
Venture Round in 2000
A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.
Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.
WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.
Infitel International
Seed Round in 1999
Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Breonics focuses on biomedical research and development, specifically in the area of organ and tissue transplants. The company has developed Exsanguinous Metabolic Support (EMS) technology, which significantly expands the criteria for organ donation. This innovative technology addresses the limitations that currently restrict access to potential kidney donors, allowing healthcare practitioners to maintain the oxidative metabolism and function of organs while they are isolated from the human body. As a result, EMS has the potential to double the number of transplantable kidneys available worldwide, ultimately improving outcomes for patients in need of transplants.
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.
Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.
EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in developing innovative pharmaceutical products aimed at treating pain and cancer. The company employs a unique topical delivery approach for its prescription pain medications, which allows for targeted drug administration, distinguishing its products from traditional systemic or transdermal methods. EpiCept is focused on establishing partnerships for co-marketing, co-promotion, licensing, and distribution of its products, thereby enhancing its market presence. The company has implemented a robust patent strategy to protect its product portfolio, which is anticipated to possess significant market potential.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.
MediGene is a biotechnology company that focuses on immuno-oncology, specifically developing engineered T cell receptor (TCR-T) therapies aimed at treating various solid tumors with significant unmet medical needs. The company operates primarily in two segments: Immunotherapies, which include T-cell receptor-based adoptive T-cell therapies and dendritic cell (DC) vaccines, and Other products. MediGene has a presence in the United States, Germany, and Asia, with most of its revenue generated from its operations in Germany. Through its innovative therapies, MediGene aims to address critical challenges in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.